IL21 and type 1 diabetes mellitus: A recently published multicenter RCT investigated whether the combination of anti-interleukin (IL)-21 antibody combined with liraglutide would better enable ß-cell survival when compared to IL-21 or liraglutide alone or placebo in recently diagnosed individuals with T1D.